Table 3.
Medications in Development for Treatment of Various Soft Tissue Sarcoma Histologies.
| Medication | Mechanism of Action | Target | Sarcoma Type | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Nirogacestat AL102 |
γ-Secretase Inhibitors | Notch and Wnt/β-catenin pathway | Desmoid Tumor |
NCT03785964 NCT04871282 |
| Anlotinib | Tyrosine Kinase Inhibitor | VEGFR-2,-3; FGFR-1,-4; PDGFR-α,-β; c-Kit; Ret |
ASPS Synovial Sarcoma Leiomyosarcoma |
NCT03016819 |
| Milademetan BI 907828 |
MDM2 Inhibitor | P53 | WD/DD LPS |
NCT04979442 NCT03449381 |
| Vimseltinib | Tyrosine Kinase Inhibitor | CSF1R | TGCT | NCT05059262 |
| CFT8634 FHD-609 |
BRD9 Inhibitor | ncBAF Complex | Synovial Sarcoma SMARCB1-Loss Tumors |
NCT05355753 NCT04965753 |
Vascular endothelial growth factor receptor (VEGFR); platelet derived growth factor receptor (PDGFR); fibroblast growth factor receptor (FGFR); alveolar Soft Part Sarcoma (ASPS); well-differentiated/dedifferentiated liposarcoma (WD/DD LPS); Murine Double Minute Clone 2 (MDM2); tenosynovial Giant Cell Tumor (TGCT).